Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SANDU PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANDU PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
SANDU PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 86 | 319 | - | |
Low | Rs | 50 | 230 | - | |
Sales per share (Unadj.) | Rs | 67.6 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 1.6 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 2.1 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 0.75 | 0 | - | |
Avg Dividend yield | % | 1.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 40.6 | 74.5 | - | |
Shares outstanding (eoy) | m | 9.66 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 2.9 | 34.8% | |
Avg P/E ratio | x | 43.3 | -11.5 | -377.0% | |
P/CF ratio (eoy) | x | 32.3 | -13.9 | -233.2% | |
Price / Book Value ratio | x | 1.7 | 3.7 | 45.5% | |
Dividend payout | % | 47.6 | 0 | - | |
Avg Mkt Cap | Rs m | 658 | 46,340 | 1.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 111 | 2,908 | 3.8% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 653 | 16,016 | 4.1% | |
Other income | Rs m | 3 | 112 | 2.9% | |
Total revenues | Rs m | 657 | 16,128 | 4.1% | |
Gross profit | Rs m | 25 | -2,775 | -0.9% | |
Depreciation | Rs m | 5 | 691 | 0.7% | |
Interest | Rs m | 1 | 434 | 0.2% | |
Profit before tax | Rs m | 22 | -3,788 | -0.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 7 | 237 | 2.9% | |
Profit after tax | Rs m | 15 | -4,036 | -0.4% | |
Gross profit margin | % | 3.8 | -17.3 | -22.0% | |
Effective tax rate | % | 31.4 | -6.2 | -502.6% | |
Net profit margin | % | 2.3 | -25.2 | -9.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 255 | 11,730 | 2.2% | |
Current liabilities | Rs m | 139 | 6,600 | 2.1% | |
Net working cap to sales | % | 17.8 | 32.0 | 55.7% | |
Current ratio | x | 1.8 | 1.8 | 103.5% | |
Inventory Days | Days | 65 | 111 | 58.3% | |
Debtors Days | Days | 268 | 124 | 216.0% | |
Net fixed assets | Rs m | 286 | 6,838 | 4.2% | |
Share capital | Rs m | 97 | 74 | 129.9% | |
Net worth | Rs m | 392 | 12,571 | 3.1% | |
Long term debt | Rs m | 0 | 4,418 | 0.0% | |
Total assets | Rs m | 542 | 23,747 | 2.3% | |
Interest coverage | x | 28.7 | -7.7 | -371.2% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.7 | 178.9% | |
Return on assets | % | 3.0 | -15.2 | -19.5% | |
Return on equity | % | 3.9 | -32.1 | -12.1% | |
Return on capital | % | 5.9 | -19.8 | -29.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2 | 1,367 | 0.2% | |
From Investments | Rs m | 5 | -420 | -1.3% | |
From Financial Activity | Rs m | 6 | 4,009 | 0.1% | |
Net Cashflow | Rs m | 13 | 4,957 | 0.3% |
Compare SANDU PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SANDU PHARMA With: SHELTER PHARMA NECTAR LIFESCIENCE INNOVA CAPTAB LTD. STRIDES PHARMA SCIENCE ALCHEMIST LIMITED
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.